Nykode Therapeutics : ESG Report 2022

ESG REPORT 2022

ESG highlights

Number of employees	Number of clinical trials,
155	ongoing and applied for
5

Regulatory breaches	Waste tonnes
0	3.7

Diversity Staff

F:67%/M:33%

Diversity Board/Senior Mgmt*

F:38%/M:62%

* Board and Sr. Mgmt have same diversity %

GHG tonnes CO2e

745

(market-based)

NYKODE THERAPEUTICS ESG REPORT 2022

2

CONTENTS

CEO Statement	4
Sustainability at Nykode	5
ENVIRONMENT	6
GHG Emissions	6
Waste	6
Reducing our environmental impacts	7
SOCIAL	8
Our people	8
Socially responsible business practice	8
Recruiting and retaining exceptional talents	9
GOVERNANCE	10
Supply chain management	10
Ethics and integrity	10
Regulatory compliance	10
Reviewing human rights risks in our value chain	10
Appendix / SASB Disclosures	11

About this report

This report includes environmental, social and governance (ESG) disclosures for Nykode Therapeutics ASA (Nykode or the Company) for the annual period January 1 to December 31, 2022. Disclosures have been made following the Sustainability Accounting Standards Board (SASB, https://www.sasb.org) Biotechnology & Pharmaceuticals Standard (2018). In determination of material ESG topics to include in the report, Nykode referenced the Global Reporting Initiative (GRI) Standards' (2021) Materiality Standard (GRI 3), the opinions of its stakeholders, the reporting of industry peers, and internal and independent expert opinions. The ESG disclosures contained within this report have not been independently assured. For further information or feedback on this report, contact [e-mail].

NYKODE THERAPEUTICS ESG REPORT 2022

3

CEO STATEMENT

Entering 2023, I am proud to share our commitment to sustainability and the progress we have made in promoting responsible practices in this: our inaugural environmental, social and governance (ESG) Report

Dear reader,

As the world faces increasingly complex challenges, we at Nykode are committed to being part of the solution for a better world, ensuring healthy lives and promoting well-being for patients. Entering 2023, I am proud to share our commitment to sustainability and the progress we have made in promoting responsible practices in this: our inaugural environmental, social and governance (ESG) Report.

Our five values - courage, integrity, collaboration, re­ spect, and flexibility - guide our actions on sustainability, diversity, equity and inclusion (DE&I), and position us to be a purpose-driven leader in our industry. Our work is meaningful at its core, and we are making steady progress in our pipeline, with five clinical programs ongoing and applied for, and world class pharma collaboration partners to treat cancers and infectious diseases with a high unmet medical need.

In order to maximize the positive impact both within and outside of Nykode, we are working on better integrating ESG initiatives into our strategies and daily activities. In 2022, we established our baseline measures for greenhouse gas emissions, energy use, and waste, as a component towards reducing our environmental impacts. As a clinical-stage biotechnology company with 155 employees (per December 31, 2022), our environmental footprint is relatively small. We are reviewing

our value chain and business partners to identify where human rights risks may exist in response to the Norwe- gian Transparency Act (Åpenhetsloven). We are currently formalizing our reporting systems to further communicate our ESG targets in this annual ESG report format.

The pharma and biotech industry operates within a regulated framework aiming to support meaningful medical innovation. Our clinical trials are performed in accordance with the ethical and scientific principles governing clinical research on human subjects outlined in the Declaration of Helsinki and the International Conference on Harmonization, and we handle personal data in accordance with the General Data Protection Regulati- on. Headquartered and publicly listed in Norway, Nykode appreciates the incorporation of the Transparency Act as national law. We maintain a close and diligent relationship with our suppliers and clinical partners to ensure that our trials are carried out responsibly and their manufacturing facilities are conforming to Current Good Manufacturing Practices.

We recognize our critical role in promoting sustainable and responsible practices. During a time of global uncertainty due to inflation and geopolitical tensions, we are taking concrete actions to identify and manage the issues that are most important to our stakeholders.

On behalf of the leadership team at Nykode, I would like to thank patients, our colleagues and partners for their efforts and contributions over the past year. I invite you to read our report and welcome your feedback.

Sincerely,

Michael Engsig

Chief Executive Officer

NYKODE THERAPEUTICS ESG REPORT 2022

4

SUSTAINABILITY AT NYKODE

The purpose of Nykode is to deliver improved outcomes for human health. Our focus on sustainability includes environmental, social and governance matters which create value for society and our business. Responsibility for Nykode's ESG performance is ultimately held by the Board of Directors and ESG initiatives are managed by the CEO, with specific functions

delegated­ to members of the management team. The CFO has responsibility for reporting on ESG performance. Nykode's sustainability ­framework includes management of the material ESG topics of the business:

Regulatory compliance

Ethics and integrity

	Greenhouse gas
Environment	(GHG) emissions

Waste

Governance

Supply chain management

Social

Our people

Socially responsible business practice

NYKODE THERAPEUTICS ESG REPORT 2022

5